SOLV vs. GEHC, PHG, ZBH, SNN, PEN, STVN, GKOS, IRTC, NARI, and TMDX
Should you be buying Solventum stock or one of its competitors? The main competitors of Solventum include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Inari Medical (NARI), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
Solventum vs. Its Competitors
Solventum (NYSE:SOLV) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
GE HealthCare Technologies has higher revenue and earnings than Solventum. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.
82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.1% of Solventum shares are owned by company insiders. Comparatively, 0.3% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, GE HealthCare Technologies had 7 more articles in the media than Solventum. MarketBeat recorded 23 mentions for GE HealthCare Technologies and 16 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 1.28 beat Solventum's score of 1.22 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.
Solventum currently has a consensus target price of $81.50, indicating a potential upside of 4.21%. GE HealthCare Technologies has a consensus target price of $88.27, indicating a potential upside of 15.97%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, analysts clearly believe GE HealthCare Technologies is more favorable than Solventum.
Solventum has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
GE HealthCare Technologies has a net margin of 11.02% compared to Solventum's net margin of 4.55%. Solventum's return on equity of 31.01% beat GE HealthCare Technologies' return on equity.
Summary
GE HealthCare Technologies beats Solventum on 14 of the 17 factors compared between the two stocks.
Get Solventum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOLV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solventum Competitors List
Related Companies and Tools
This page (NYSE:SOLV) was last updated on 7/3/2025 by MarketBeat.com Staff
